Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saquinavir Clear all
Completed Phase 2 Interventional

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

NCT00002448
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Efavirenz, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Results available

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

NCT00435929
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, saquinavir [Invirase]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • Somers Point, New Jersey • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 2, 2026, 5:42 AM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

NCT00046033
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Amprenavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • Honolulu, Hawaii • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

NCT00002378
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
97
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

NCT00002333
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Harbor City, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

Directly Observed Therapy in High Risk Populations in Newark, NJ

NCT00285883
View directory record Official record
Conditions
Directly Observed Therapy, HIV Infections
Interventions
Invirase, Norvir
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2006 · Synced Sep 2, 2026, 5:42 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

NCT00102206
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1Phase 2 Interventional

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195
View directory record Official record
Conditions
HIV Infections
Interventions
FDA Approved Antiretroviral Therapy (see list below)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00003008
View directory record Official record
Conditions
Sarcoma
Interventions
indinavir sulfate, nelfinavir mesylate, paclitaxel, ritonavir, saquinavir mesylate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

NCT00000920
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Ritonavir, Saquinavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002382
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00002380
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 13 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, PI, RTV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

NCT00002190
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Sherman Oaks, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

NCT00004584
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Ritonavir, Saquinavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 2, 2026, 5:42 AM EDT